Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
Company Presentation Announcement: Vericel Corporation will present at the Bank of America Securities 2025 Healthcare Conference on May 14, 2025, with a webcast available on their Investor Relations website.
About Vericel Corporation: Vericel specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI and Epicel, as well as holding rights to NexoBrid for burn treatment.
Trade with 70% Backtested Accuracy
Analyst Views on VCEL
About VCEL
About the author
Vericel Corporation (VCEL) Expects $276 Million Revenue in 2025 with Continued Profitability
- Financial Outlook: Vericel anticipates total net revenue of approximately $276 million for 2025, with MACI net revenue of $239.5 million, reflecting a 23% growth in Q4, indicating sustained competitive strength in the market.
- Profitability Improvement: The company expects to achieve GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%, which will provide robust financial backing for future investments and expansions.
- Operational Achievements: Vericel has reached a quarterly record in MACI implants and trained surgeons, with over 900 MACI-trained surgeons, and plans to commence commercial manufacturing in a new facility in 2026, showcasing strong growth potential.
- Market Performance: Despite a downturn in the broader market, Vericel's stock rose 2.92% to $37.66, reflecting unique company-specific momentum, although the stock has decreased by 36.77% over the past 12 months.
VCEL Stock Shows Significant Volatility with 52-Week High of $63
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
American Express and Snowflake See Significant Options Trading Volume Surge
- American Express Options Trading: American Express (AXP) saw options trading volume reach 12,030 contracts, equivalent to approximately 1.2 million shares, representing about 47.1% of its average daily trading volume of 2.6 million shares over the past month, indicating heightened market interest in its future performance.
- High Strike Call Options: The $382.50 strike call option expiring on December 26, 2025, recorded a trading volume of 1,611 contracts today, representing around 161,100 underlying shares, suggesting increased investor expectations for a rise in American Express's stock price.
- Snowflake Options Trading: Snowflake (SNOW) experienced options trading volume of 29,100 contracts, translating to approximately 2.9 million shares, or about 45% of its average daily trading volume of 6.5 million shares over the past month, reflecting strong market confidence in its growth prospects.
- High Strike Call Options: The $225 strike call option expiring on December 26, 2025, saw a trading volume of 2,751 contracts today, equivalent to approximately 275,100 underlying shares, indicating optimistic sentiment among investors regarding Snowflake's future performance.
Inaugural Week of VCEL Options Trading for February 2026
Put Contract Overview: The $30.00 put contract has a bid of 25 cents, allowing investors to buy VCEL shares at a cost basis of $29.75, which is a 16% discount from the current price of $35.81. There is a 78% chance the contract may expire worthless, offering a potential 0.83% return on cash commitment.
Call Contract Overview: The $45.00 call contract has a bid of 10 cents, enabling investors to sell VCEL shares at that price, which represents a 26% premium over the current stock price. If the contract expires worthless, investors keep their shares and the premium, yielding a 0.28% extra return.
Volatility Insights: The implied volatility for the put contract is 74%, while the call contract has an implied volatility of 88%. The actual trailing twelve-month volatility is calculated at 49%.
YieldBoost Tracking: Stock Options Channel will monitor and publish the odds of both the put and call contracts expiring worthless over time, providing insights into potential returns and trading history for investors.
Vericel Scheduled to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
Company Announcement: Vericel Corporation will participate in a fireside chat at the Stephens Annual Investment Conference on November 20, 2025, at 11:00 a.m. ET, with a webcast available on their Investor Relations website.
Company Overview: Vericel is a leader in advanced therapies for sports medicine and severe burn care, offering innovative cell therapies and specialty biologics to repair injuries and restore lives.
Product Portfolio: The company markets three main products in the U.S.: MACI® for knee cartilage repair, Epicel for skin replacement in burn patients, and holds rights to NexoBrid for eschar removal in burn treatment.
Contact Information: For investor inquiries, Eric Burns can be reached via email at ir@vcel.com or by phone at +1 (734) 418-4411.
Truist Reduces Price Target for Vericel Corporation (VCEL) from $46 to $41
Vericel Corporation Overview: Vericel Corporation (NASDAQ: VCEL) is recognized as a promising small-cap stock, with Truist recently lowering its price target from $46 to $41 while maintaining a Buy rating, anticipating healthy Q3 revenue despite potential stock volatility.
Product Portfolio and Market Position: The company specializes in patient-specific cellular therapies, including products like Epicel for skin replacement and MACI for tissue engineering, although some analysts suggest that certain AI stocks may present better investment opportunities with less risk.
Vericel Corporation (VCEL) Expects $276 Million Revenue in 2025 with Continued Profitability
- Financial Outlook: Vericel anticipates total net revenue of approximately $276 million for 2025, with MACI net revenue of $239.5 million, reflecting a 23% growth in Q4, indicating sustained competitive strength in the market.
- Profitability Improvement: The company expects to achieve GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%, which will provide robust financial backing for future investments and expansions.
- Operational Achievements: Vericel has reached a quarterly record in MACI implants and trained surgeons, with over 900 MACI-trained surgeons, and plans to commence commercial manufacturing in a new facility in 2026, showcasing strong growth potential.
- Market Performance: Despite a downturn in the broader market, Vericel's stock rose 2.92% to $37.66, reflecting unique company-specific momentum, although the stock has decreased by 36.77% over the past 12 months.
VCEL Stock Shows Significant Volatility with 52-Week High of $63
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
American Express and Snowflake See Significant Options Trading Volume Surge
- American Express Options Trading: American Express (AXP) saw options trading volume reach 12,030 contracts, equivalent to approximately 1.2 million shares, representing about 47.1% of its average daily trading volume of 2.6 million shares over the past month, indicating heightened market interest in its future performance.
- High Strike Call Options: The $382.50 strike call option expiring on December 26, 2025, recorded a trading volume of 1,611 contracts today, representing around 161,100 underlying shares, suggesting increased investor expectations for a rise in American Express's stock price.
- Snowflake Options Trading: Snowflake (SNOW) experienced options trading volume of 29,100 contracts, translating to approximately 2.9 million shares, or about 45% of its average daily trading volume of 6.5 million shares over the past month, reflecting strong market confidence in its growth prospects.
- High Strike Call Options: The $225 strike call option expiring on December 26, 2025, saw a trading volume of 2,751 contracts today, equivalent to approximately 275,100 underlying shares, indicating optimistic sentiment among investors regarding Snowflake's future performance.
Inaugural Week of VCEL Options Trading for February 2026
Put Contract Overview: The $30.00 put contract has a bid of 25 cents, allowing investors to buy VCEL shares at a cost basis of $29.75, which is a 16% discount from the current price of $35.81. There is a 78% chance the contract may expire worthless, offering a potential 0.83% return on cash commitment.
Call Contract Overview: The $45.00 call contract has a bid of 10 cents, enabling investors to sell VCEL shares at that price, which represents a 26% premium over the current stock price. If the contract expires worthless, investors keep their shares and the premium, yielding a 0.28% extra return.
Volatility Insights: The implied volatility for the put contract is 74%, while the call contract has an implied volatility of 88%. The actual trailing twelve-month volatility is calculated at 49%.
YieldBoost Tracking: Stock Options Channel will monitor and publish the odds of both the put and call contracts expiring worthless over time, providing insights into potential returns and trading history for investors.
Vericel Scheduled to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
Company Announcement: Vericel Corporation will participate in a fireside chat at the Stephens Annual Investment Conference on November 20, 2025, at 11:00 a.m. ET, with a webcast available on their Investor Relations website.
Company Overview: Vericel is a leader in advanced therapies for sports medicine and severe burn care, offering innovative cell therapies and specialty biologics to repair injuries and restore lives.
Product Portfolio: The company markets three main products in the U.S.: MACI® for knee cartilage repair, Epicel for skin replacement in burn patients, and holds rights to NexoBrid for eschar removal in burn treatment.
Contact Information: For investor inquiries, Eric Burns can be reached via email at ir@vcel.com or by phone at +1 (734) 418-4411.
Truist Reduces Price Target for Vericel Corporation (VCEL) from $46 to $41
Vericel Corporation Overview: Vericel Corporation (NASDAQ: VCEL) is recognized as a promising small-cap stock, with Truist recently lowering its price target from $46 to $41 while maintaining a Buy rating, anticipating healthy Q3 revenue despite potential stock volatility.
Product Portfolio and Market Position: The company specializes in patient-specific cellular therapies, including products like Epicel for skin replacement and MACI for tissue engineering, although some analysts suggest that certain AI stocks may present better investment opportunities with less risk.
